ERSP calls for Web disclosures from Urban Nutrition
The operator of WeKnowDiets.com and other Web sites should clarify that it markets weight-loss supplement MiracleBurn - featured as the "most popular" product and a "customer choice award" winner on the site - according to the Electronic Retailing Self-Regulation Program. Urban Nutrition presented WeKnowDiets.com as a review forum for diet products, though a challenger argued to ERSP that the site "is premised on a deliberate intent to mislead consumers" by disguising ads as independent product reviews. The CBBB program recommended Aug. 11 that the firm disclose its material connection to the products it endorses. New York-based Urban Nutrition said it will "follow the ERSP's recommendations to reinforce several aspects of effective disclosure methods.
More from Archive
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
Pink Sheet reporter and editors discuss the most recent senior staff departures at the FDA and their impact on the agency, as well as Commissioner Martin Makary’s plans for a new approval pathway and a combined adverse event database as outlined in an interview with a podcast host.
The European Medicines Agency has recommended 16 drugs for EU-wide approval, including Vertex’s cystic fibrosis drug Alyftrek and five other orphans.
The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.